Lv51
1450 积分 2021-06-22 加入
Resistance to Trastuzumab
2小时前
已完结
HER2-Positive Breast Cancer Treatment and Resistance
2小时前
已完结
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives
2小时前
已完结
CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment
2小时前
已完结
Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast Cancer
2小时前
已完结
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
2个月前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
2个月前
已完结
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
2个月前
已完结
JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies
2个月前
已关闭
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2个月前
已完结
皖公网安备34019202002308
